ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 26.0 | 22.8 | 33.4 |
| Other income | 0.0 | 0.0 | 0.1 |
| Total income | 26.0 | 22.8 | 33.5 |
| Profit before exceptional items & tax | 2.4 | 3.2 | 3.9 |
| Profit before tax | 2.4 | 3.2 | 3.9 |
| Net profit | 2.0 | 3.0 | 3.7 |
| Operating margin | 9.2% | 14.0% | 11.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -45.90% |
|---|---|
| Net profit, quarter on quarter | -33.30% |
| Revenue, year on year | -22.20% |
NSE results filing, NSE: INDOUS. Figures extracted from the filing.
Indo US Bio-Tech Ltd: key numbers
- Share price
- ₹65.33
- Market cap
- ₹131.0 Cr
- Revenue (annual)
- ₹110.4 Cr
- Net profit (annual)
- ₹13.12 Cr
- P/E (TTM)
- 30.2×Sector 29.0×
- Promoter holding
- 68.29%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indo US Bio-Tech Ltd
All →Indo US Bio-Tech Q2 FY27 Results: Net Loss of ₹3.7 Cr
Indo US Bio-Tech Ltd reported revenue from operations of ₹15 Cr (-51.3% YoY) and a net loss of ₹3.7 Cr for Q2 FY27.
- Key figure
- Net loss ₹3.7 Cr
Indo US Bio-Tech Board Meeting Date
Indo Us Bio-Tech has intimated that its board will meet on 30 October 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The notice is advance intimation only, with no results yet reported.
Indo US Bio-Tech Business Update
Indo Us Bio-Tech disclosed promoter invitations to attend China's 140th Canton Fair. The filing states no financial value or business commitment.
Indo US Bio-Tech Other Announcement
Indo Us Bio-Tech Ltd filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Indo US Bio-Tech Annual General Meeting
Indo Us Bio-Tech Limited held its 22nd Annual General Meeting on September 30, 2026. The filing provides a gist of the meeting's proceedings and agenda items.
Indo US Bio-Tech Annual Report
Indo Us Bio-Tech Ltd submitted its Annual Report for FY 2025-2026. The 22nd Annual General Meeting is scheduled for September 30, 2026.